Dehydroepiandrosterone (DHEA) is the most abundant steroid hormone in the human body, produced primarily by the adrenal cortex and to a lesser extent by the gonads and brain, serving as the principal precursor for sex hormone biosynthesis including testosterone and estrogens. DHEA levels peak in the mid-20s and decline dramatically with age (approximately 80-90% by age 70-80), a phenomenon termed 'adrenopause,' making DHEA supplementation a subject of extensive anti-aging and hormonal research. Both oral DHEA and its sulfated form DHEA-S (dehydroepiandrosterone sulfate) are studied for effects on body composition, sexual function, immune modulation, cognitive function, and mood.
What Is DHEA (Dehydroepiandrosterone)?
Dehydroepiandrosterone, commonly abbreviated DHEA, is an endogenous C19 steroid hormone and a major intermediate in human steroidogenesis. It is synthesized mainly in the zona reticularis of the adrenal cortex from cholesterol, although smaller amounts are produced in the gonads, skin, and nervous system. Adrenal cholesterol is converted through pregnenolone and 17-hydroxypregnenolone to DHEA by the enzymes CYP11A1, CYP17A1, and related hydroxysteroid dehydrogenases. DHEA is often described as an androgen precursor because peripheral tissues can convert it to androstenedione, testosterone, dihydrotestosterone, estrone, and estradiol. It is not, however, simply a circulating form of testosterone: its biological effects vary with tissue-specific enzymes, receptor expression, age, sex, and local conversion pathways.
DHEA secretion rises during adrenarche, increases through adolescence, and generally reaches its highest circulating concentration during the second or third decade of life. Thereafter, levels decline progressively, often reaching approximately 10-20% of young-adult concentrations by the seventh or eighth decade. This age-associated fall is sometimes called adrenopause, although it is not a universally accepted clinical diagnosis and does not necessarily represent a disease state. Most circulating DHEA is rapidly sulfated by steroid sulfotransferase to form DHEA sulfate, or DHEA-S. DHEA-S is generally present at concentrations roughly tenfold higher than free DHEA and has a substantially longer half-life, making it a more stable clinical marker of adrenal androgen production. DHEA can also be synthesized locally in the brain, where it and DHEA-S act as neurosteroids. Research on DHEA expanded notably during the 1980s and 1990s as investigators explored aging, immune function, mood, and sexual physiology. The 2000s brought larger randomized trials and more critical reviews, and contemporary work focuses on carefully defined deficiencies, vaginal prasterone, tissue-specific actions, and the distinction between biochemical associations and clinically meaningful benefits.
Research Indications
Adrenal Insufficiency Replacement
Well-being and fatigue
Randomized studies in people with primary or secondary adrenal insufficiency have reported modest improvements in well-being, fatigue, or mood with DHEA replacement, although effects are variable.
Female sexual function
In women with adrenal insufficiency, physiologic DHEA replacement has shown benefits for libido and sexual interest in some trials; androgenic adverse effects can limit use.
Age-Related Hormonal Decline
Body composition and physical function
DHEA levels decline with age, but controlled trials in healthy older adults have generally found little or no clinically meaningful improvement in muscle strength, physical performance, or body composition.
Bone and metabolic markers
Some studies suggest small changes in bone turnover, bone density, or insulin sensitivity in selected populations, but findings are inconsistent and not sufficient to establish an anti-aging indication.
Mood and Depressive Symptoms
Adjunctive depression research
Small clinical trials and meta-analyses have suggested possible antidepressant effects, particularly in midlife populations, but study size, duration, and dosing heterogeneity limit certainty.
Cognitive outcomes
Evidence does not reliably support DHEA for cognition or dementia prevention. Neuroactive steroid mechanisms remain an active research area rather than an established use.
Sexual Health in Midlife
Postmenopausal symptoms
Oral DHEA has not consistently improved menopausal symptoms or sexual function in otherwise healthy postmenopausal women; local vaginal DHEA is a distinct treatment with different exposure and evidence.
Androgen precursor activity
DHEA can convert peripherally to androgens and estrogens. Resulting hormonal effects differ substantially by sex, age, tissue enzyme activity, and baseline endocrine status.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Adrenal insufficiency replacement research | 25–50 mg | Once daily | Oral |
| Female well-being and libido studies | 25–50 mg | Once daily | Oral |
| Healthy older-adult trials | 50 mg | Once daily | Oral |
| Depression research protocols | 30–90 mg | Once daily | Oral |
Timing
Research protocols commonly administer DHEA in the morning to approximate its normal circadian pattern and reduce the chance of sleep disruption. Hormone-related effects and adverse effects may take several weeks to assess; supervised monitoring is particularly important for long-term use.
Peptide Interactions
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
The components have different research mechanisms and may be scheduled around training, feeding, or metabolic assessments. Evidence for the exact combination is limited, so timing should be documented to avoid confounding endpoint interpretation.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
These compounds address different research mechanisms represented in this preset. This is mechanistic complementarity, not evidence of clinical synergy: controlled studies of the exact combination are limited or unavailable, so interpret each exposure and safety signal independently.
DHEA is an androgen precursor and may add to androgenic effects such as acne, oily skin, hair changes, or mood changes when combined with testosterone therapy.
Peripheral conversion of DHEA to estrogens may alter total hormonal exposure. Use requires clinician review in people receiving menopausal hormone therapy or with estrogen-sensitive conditions.
Because DHEA can serve as a precursor for sex steroids, unsupervised use may conflict with endocrine therapy for hormone-sensitive cancers. Oncology approval is essential.
DHEA may affect insulin sensitivity and glucose metabolism. People using antidiabetic medicines should monitor glucose and discuss use with their prescriber.
Potential effects on platelets and bleeding risk are not well characterized. Medical review is prudent when DHEA is combined with warfarin, direct oral anticoagulants, aspirin, or similar agents.
Both are steroid-hormone precursors, but combined supplementation can make hormone effects less predictable. There is no established evidence-based benefit to combining them routinely.
Reported Research Timeline
01Days 1–7 (reported in cited studies): some people notice no immediate change. Sensitive individuals may experience sleep changes, increased energy, irritability, acne, or oily skin early in exposure.
02Weeks 2–4 (reported in cited studies): circulating DHEA-S generally rises with regular dosing. Any changes in mood, libido, or perceived well-being are typically assessed over this interval rather than after a single dose.
03Weeks 4–8 (reported in cited studies): in adrenal-insufficiency research, modest changes in fatigue, well-being, or sexual interest may become apparent. Lack of benefit should be weighed against androgenic adverse effects.
04Months 2–3 (reported in cited studies): if used under clinical supervision, this is a practical interval to review symptoms, blood pressure, lipids, glucose markers, and hormone-related adverse effects where appropriate.
05Months 3–6 (reported in cited studies): longer trials have not consistently shown broad anti-aging, strength, cognitive, or body-composition benefits in healthy older adults.
06Ongoing (reported in cited studies): continued use should be periodically reassessed with a clinician, especially in people with prostate, breast, ovarian, uterine, metabolic, mood, or cardiovascular risk factors.
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
DHEA is a hormone precursor, not a nutritionally essential vitamin. It can increase androgen and estrogen exposure in a tissue-dependent manner.
Common androgenic effects include acne, oily skin, increased facial or body hair, scalp-hair changes, and menstrual irregularity. These may be more prominent at higher doses.
Avoid self-treatment during pregnancy or breastfeeding because fetal and infant hormonal effects are unknown and potentially significant.
People with a history of bipolar disorder, mania, severe anxiety, or insomnia should use particular caution, as hormonal agents can affect mood and sleep.
Clinician-guided use is advised for adrenal insufficiency; DHEA does not replace glucocorticoid or mineralocorticoid therapy and should not be used to manage an adrenal crisis.
Seek Medical Attention If:
You develop chest pain, shortness of breath, fainting, one-sided weakness, or symptoms suggestive of a serious cardiovascular event.
You experience severe agitation, racing thoughts, markedly reduced need for sleep, mania, suicidal thoughts, or other acute mental-health symptoms.
You develop signs of an allergic reaction, including facial or throat swelling, wheezing, widespread hives, or difficulty breathing.
You have unexplained vaginal bleeding, rapid virilization, breast changes, urinary obstruction symptoms, or other concerning hormone-related symptoms.
Quality Indicators
Verified Marker
Lot-specific certificate of analysis
Choose a product with a batch or lot-specific COA that identifies the tested material, reports assay results, and is accessible before purchase.
Verified Marker
Independent identity and purity testing
Prefer transparent third-party testing using an appropriate analytical method, such as HPLC or LC-MS, with stated DHEA identity and purity results.
Verified Marker
Heavy-metal and microbiological screening
Quality documentation should include screening for heavy metals and, for finished capsules, relevant microbiological contaminants.
Acceptable Range
Clear capsule strength and excipient disclosure
The label should state DHEA amount per capsule, serving size, inactive ingredients, lot number, expiry date, and manufacturer contact information.
Quality Concern
Proprietary blends or unverifiable testing claims
Avoid products that obscure the DHEA dose, provide only generic certificates, lack a lot number, or claim pharmaceutical equivalence without verifiable documentation.
Research Citations
- Dehydroepiandrosterone replacement in women with adrenal insufficiency
Arlt, W., Callies, F., van Vlijmen, J. C., et al., 1999, New England Journal of Medicine - DHEA in elderly women and DHEA or testosterone in elderly men
Nair, K. S., Rizza, R. A., O'Brien, P., et al., 2006, New England Journal of Medicine - Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue
Baulieu, E. E., Thomas, G., Legrain, S., et al., 2000, Proceedings of the National Academy of Sciences of the United States of America - Dehydroepiandrosterone replacement in women with adrenal insufficiency: a randomized trial
Gurnell, E. M., Hunt, P. J., Curran, S. E., et al., 2008, Journal of Clinical Endocrinology and Metabolism - Dehydroepiandrosterone for depressive symptoms: a systematic review and meta-analysis of randomized controlled trials
Peixoto, C., Devicari, C., Fuchs, T., et al., 2014, Journal of Affective Disorders
adrenal hormone, androgen precursor, estrogen precursor, anti-aging, adrenopause, testosterone, body composition, cognitive function, immune modulation, mood, sexual function